Jul 24 |
ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
|
Jul 23 |
ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
|
Jul 22 |
ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel
|
Jul 17 |
ChromaDex appoints James Lee as interim CFO
|
Jul 16 |
ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen® Will Debut at Leading Wellness Clinics in August
|
Jul 12 |
When Will ChromaDex Corporation (NASDAQ:CDXC) Turn A Profit?
|
Jul 1 |
ChromaDex to join Russell 2000 Index
|
Jul 1 |
ChromaDex to Join Russell 2000® Index
|
Jun 26 |
ChromaDex: Looking To Take The Big Step Into Pharma
|
Jun 24 |
Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)
|